Fda accepts regen-cov® (casirivimab and imdevimab) for priority review for treatment and prophylaxis of covid-19

Tarrytown, n.y., oct. 14, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has accepted for priority review a biologics license application (bla) for regen-cov® (casirivimab and imdevimab) to treat covid-19 in non-hospitalized patients and as prophylaxis in certain individuals.
REGN Ratings Summary
REGN Quant Ranking